drugset / Trial / NCT01470937

Early Diabetes Intervention Program

NCT01470937

Phase 4 Completed 219 enrolled Indiana University Bayer · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is an evaluation of the effect of acarbose to delay worsening of fasting glucose control in early Type 2 diabetes mellitus.

Timeline

Start
1998-02
Primary completion
2004-09
Completion
2004-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Acarbose Unknown 100 mg Oral